Clinical Trial Update: Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 comparative trial comparing CMAB015 with Secukinumab for moderate to severe plaque psoriasis is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• CMAB015
• Secukinumab (secukinumab)

Snippet

Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Conditions: Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING